Introduction

Background
In 1993, the Joint National Committee Report-5 (JNC-5) recommended a blood pressure (BP) treatment goal of <130/85 mmHg 1 for diabetic patients, relying on subgroup data from the diabetic patients enrolled in the Hypertension Optimal Treatment (HOT) trial 2 . This was later harshly criticised in a Cochrane review 3 . Data from the UKPDS group 4, 5 showed that diabetic and hypertensive patients with a tight BP goal had better macrovascular and microvascular outcomes; however, the 'tight BP goal group' reached a mean systolic blood pressure (SBP) of 144 mmHg versus 155 mmHg in the usual care group.
In 2002 the American Diabetes Association recommended a treatment goal of <130/80 mmHg 6 for diabetic patients and stated, 'There is not a threshold value for BP; risk continues to decrease well into the normal range' 7 .
In 2003, the JNC-7 8 , and guidelines from many other international societies, con irmed the treatment goal of <130/80 mmHg for patients with diabetes and those with chronic kidney disease (CKD), and in 2007, an AHA Scienti ic Statement extended this goal to patients with coronary artery disease (CAD), myocardial infarction and angina.
The 2013 European Society of Hypertension-European Society of Cardiology (ESH-ESC) Guidelines 9 , without underlining the fact that for two decades an international consensus, with isolated discordant voices, pushed to treat to unrealistic and unproven targets, just admitted that 'The 2007 Guidelines, in common with other guidelines, recommended two distinct BP targets: <140/90 in (all) low-moderate risk hypertensives and <130/80 in high-risk hypertensives with diabetes, cerebrovascular, cardiovascular disease (CVD), or renal disease,' including very elderly people.
Since the National Heart, Lung, and Blood Institute stopped the publication of practice guidelines, the European Guidelines 9 provide the most comprehensive recommendations available.
This review does not intend to summarise and comment the ESH-ESC Guidelines (76 pages) but just discusses some new and/or recurring problems that are very relevant for public health. For high-normal BP, ESH reappraisal admitted that evidence for antihypertensive drugs is scanty at best. In addition, two large RCTs in which subjects with pre-diabetes or metabolic syndrome with high-normal BP had received ramipril (DREAM) or valsartan (NAVIGATOR) showed no reduction in cardiovascular events. Finally, in large meta-analyses that show the bene its of antihypertensive drugs even in patients with SBP <140 mmHg, most of these patients were not truly normotensive but were already under the effect of hypertension therapies.
The 2013 ESH-ESC
Summing up, in high-normal BP the intervention should be limited to lifestyle changes, and antihypertensive drugs are not recommended even for patients with CVD or CKD and diabetic patients with organ damage or multiple risk factors (in the absence of necessary evidence of bene it).
In Grade 1 hypertension BP drugs are recommended for patients with organ damage, CKD Grade ≥ 3, diabetes or symptomatic CVD, but targeting <140/90 mmHg.
Antihypertensive drug treatment should also be considered for patients with low to moderate risk, especially when BP remains within Grade 1 range despite modi ication of lifestyle for several weeks (or several months, in the absence of other risk factors).
In the elderly, hypertensive drug therapy is recommended for those having SBP ≥160 mmHg, and an SBP between 140 and 159 may be considered for those aged <80 years, provided it is well tolerated.
New unified BP target
Here are the new targets:
• A subgroup analysis of the African American Study of Kidney Disease and Hypertension (AASK) RCT shows a possible bene it for the minority of patients with high proteinuria and a trend to the opposite for the remaining two-thirds of patients with less proteinuria; however, it is only a hypothesis and needs to be tested.
Target BP for organ damage studies: is there any evidence?
It is very contradictory; for example, compared with those in placebo in Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial, diabetic patients more intensively treated with olmesartan showed not only a statistically signi icant (though clinically minimal) reduction in new onset microalbuminuria but also a higher incidence of cardiovascular mortality, and -as a trend -of total mortality 13 . In Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) the BP obtained from the ramipriltelmisartan combination reduced proteinuria but without cardiovascular bene its and with increased risk of acute renal failure and dialysis (and 60 more deaths) 14 . In Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) trial patients with CVD or diabetes without macroalbuminuria received telmisartan or placebo. With telmisartan, rate of increase in albuminuria came down, but decreases in eGFR were greater, and the composite renal outcome and the number of deaths were higher, though not signi icantly 15 .
Pharmacological therapy
Guidelines conclude that 'the main bene its of antihypertensive treatment are due to lowering of BP and largely independent of the drugs employed. Therefore they recon irm that diuretics (including thiazides, and thiazide-like chlorthalidone and indapamide), beta-blockers, calciumchannel blockers (CCB), ACE inhibitors and angiotensin receptor blockers (ARBs) are all suitable for the initiation and maintenance of antihypertensive treatment, either as monotherapy or in some Combinations'. This 'liberal approach to initial monotherapy, without any intention of establishing priorities,' hides the usual bad habit to justify the use of more expensive drugs with equal effectiveness, in contrast with the Code of Conduct that all doctors should follow.
Critical therapeutic issues
A very important question in relation to public health issues is: which diuretic a practitioner should choose? This review will address this question and somewhat less obvious issue.
Diuretics
The guidelines remember that diuretics are 'still classi ied as the only irstchoice drug by which to start with, in both the JNC-7 8 and the WHO/ International Society of Hypertension Guidelines' 16 . However, the ESH-ESC Guidelines seem to give greater importance to the Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial 17 , in which the benazepril-amlodipine combination achieved signi icantly better results compared to the benazeprilhydrochlorothiazide (HCTZ) combination; however, guidelines state that 'the evidence provided by ACCOMPLISH does not appear to bear suf icient weight to exclude diuretics from irst-line choice(s)'.
In fact, ACCOMPLISH trial seems conceived to 'revive in combination' off-patent drugs, and, above all, like the Anglo-Scandinavian Cardiac Outcomes
Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) study 18 , further justi ies the use of drugs more pro itable instead of diuretics. This is further dealt with in paragraph "Why choose chlorthalidone or indapamide and not HCTZ?".
ACCOMPLISH: a commercial operation
It is stated that in ACCOMPLISH 17 amlodipine-benazepril combination has overcome the HCTZ-benazepril combination. Does this prove that amlodipine is better than thiazide or
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Licensee No, because the conclusion of ACCOMPLISH is seriously biased, as would be evident from the following observations:
1. In the largest comparative RCT ever made, the thiazidelike diuretic chlorthalidone had already been demonstrated to be equivalent to amlodipine in the primary outcome and to be clearly superior in reducing heart failure (HF) 19 , and the superiority of diuretics over CCBs to prevent HF is con irmed in all meta-analyses 20 So, whoever conceived ACCOMPLISH not only chose a comparator of convenience but also made impossible for HCTZ to compete fairly.
Unfortunately, given the lack of attention of regulators, ACCOMPLISH has served well its purpose of discrediting diuretics, since they were too inexpensive to see their role acknowledged in the treatment of hypertension.
Why choose chlorthalidone or indapamide and not HCTZ?
The current US guidelines for hypertension 8 recommend a thiazide or thiazide-like diuretic as initial drug, without showing any preference between HCTZ and chlorthalidone. HCTZ is available in various doses, from 12.5 mg onwards, and the more powerful chlorthalidone is available only in a 25-mg tablet, a dose that is excessive for most patients. Chlorthalidone is available in very few combinations, which do not include the most popular ones with ACE inhibitors or ARBs. The consumption of HCTZ is far greater. However, the following shortcomings in the use of HCTZ need attention:
• In equal mg, chlorthalidone reduced SBP better than HCTZ, with similar 26 or higher effects on the levels of potassium (see Point c. in Notes section) and less changes in cholesterol.
• Compared to HCTZ 50 mg, chlorthalidone 25 mg gives a greater 24-hour BP reduction, especially at night (13 vs. 6 mm Hg) 27 , probably due to its 5-times longer half-life compared to HCTZ.
• HCTZ showed less reduction in BP compared with other antihypertensive drugs in a meta-analysis including 19 RCTs. 28 • Reanalysis of RCT MRFIT showed that chlorthalidone is superior to HCTZ in reducing 19 Licensee Diamicron MR Controlled Evaluation (ADVANCE), Hypertension in the Very Elderly Trial (HYVET) and so on. Indapamide also achieves metabolic neutrality on glycaemia and lipaemia, less reduction in kaliemia and less increase in uricaemia.
The best evidence comes from a network meta-analysis
Without an RCT directly comparing head-to-head outcomes between chlorthalidone and HCTZ, the best solution is a network metaanalysis 22 of the nine RCTs (almost all high-quality) indirectly comparing chlorthalidone or HCTZ with a common comparator-placebo or active drugs such as amlodipine or ACE inhibitors. The meta-analysis included almost 80,000 patients, and all the results are very consistent, even when adjusted for type of comparator, level of achieved BP and retrospective comparison inside the MRFIT RCT ( Figure 1 , Table 2 ). 
Critical appraisal of the validity of relevant articles
Currently, there exists a large body of high quality scienti ic evidence that could allow an effective and cost-effective management of arterial hypertension, largely based on well conducted double blind RCTs, and whenever possible on pragmatic RCTs 19 , and on their systematic reviews. Unfortunately, many clinical guidelines do not re lect this kind of evidence, and seem to give greater importance to studies that, starting from their design, are better suited to satisfy the sponsor's needs. A paradigmatic example of such biases is the reluctance of ESH-ESC Guidelines to accept the evidence, strong and consistent though indirect, of the superiority of chlorthalidone and indapamide over HCTZ.
Conclusion
The new ESH-ESC Guidelines, after decades of increasingly aggressive target reductions, inally restore a uni ied target of <140/90 mmHg, and higher for the elderly, but continue to avoid a cost-effective approach in drug therapies, and in fact, justify the use of much more expensive strategies. One of the main mechanisms underlying this policy is to deny the superiority of thiazide-like diuretics.
Clinical applicability
From a strictly clinical perspective, the applicability of the best evidence from the set of the RCTs is very good. However, this is unlikely to occur in practice, if the incentives and incomes of physicians and of their opinion leaders will continue (being equal to the effectiveness) to be aligned to the more costly therapeutic strategies, rather to the more cost-effective ones.
a. The only drug that has reduced total mortality (not just stroke) in elderly aged >80 years is low-dose indapamide (plus an ACE inhibitor as needed) in HYVET trial. b. In ASCOT-BPLA 18 , similar arguments were supported with various arti ices, comparing amlodipine (plus perindopril as required) with the less ef icacious atenolol 31 (plus, as required, bendro luazide, underdosed and with shorter half-life). Similar biases occurred in the openlabel RCT ACCOMPLISH, also interrupted 'for obvious bene its' (although the primary outcome was not achieved). A critical analysis 32 of ASCOT-BPLA was sent to the NICE, and harsh critics have called it 'commercial speech' 33 . But ASCOT-BPLA, as ACCOMPLISH, achieved its purpose anyway. c. However, in large trials (SHEP, ALLHAT) also the minority of chlorthalidonetreated patients who developed hypokalemia had cardiovascular bene its 34 . d. A recent observational study 35 shows a nonsigni icant reduction in the primary endpoint in comparisons made between chlorthalidone and HCTZ. But its serious laws are discussed in Roush et al. 36 e. The difference in price between the two drugs is modest, but not irrelevant:
3.5 million €/year for each 100,000 patients.
